Monkeypox concept stock Emergent receives $400 million vaccine order, surges more than 8% in early trading
Emergent BioSolutions has received orders for approximately $400 million worth of smallpox, anthrax, and monkeypox vaccines, expected to be delivered in 2024 and 2025. The stock surged more than 16% in pre-market trading and over 8% at the opening. As of now, the company has delivered nearly $210 million in customer orders and has committed to delivering over $185 million in related orders by 2025. The CEO stated that Emergent continues to lead in addressing serious viral threats
According to the financial news app Zhitong Finance, the concept stock of the US smallpox vaccine, Emergent BioSolutions (EBS.US), surged more than 16% in pre-market trading on Wednesday. The company earlier announced that it had received approximately $400 million in orders for its smallpox, anthrax, and monkeypox vaccine product portfolio, to be delivered in 2024 and 2025. As of the time of writing, the stock rose over 8% in early trading.
The biotechnology company stated that so far this year, it has delivered nearly $210 million worth of customer orders, involving its immune globulin products CNJ-016 and ACAM2000, the latter being its FDA-approved smallpox and monkeypox vaccine.
Furthermore, the company has committed to delivering over $185 million worth of orders related to CNJ-016 and ACAM2000 for the remainder of this year and 2025.
At the time of this latest announcement, Africa is grappling with an ongoing monkeypox epidemic, with the World Health Organization declaring in August of this year that the monkeypox outbreak constitutes an "international concern public health emergency."
CEO Joe Papa stated: "Emergent remains a trusted partner, providing medical countermeasures for biodefense and global health preparedness."
He added: "These incremental orders demonstrate our continued leadership in helping address serious viral threats such as smallpox and monkeypox."